NeuroOne Granted 180-Day Extension to Regain Nasdaq Compliance
NeuroOne Medical Technologies has received an additional 180 days to meet Nasdaq's minimum bid price requirement, providing crucial breathing room for the neurological device company to stabilize its stock performance and avoid potential delisting.
NeuroOne Medical Technologies Corporation has secured a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The medical technology company, which focuses on developing solutions for neurological disorders, now has until May 4, 2026, to maintain a closing bid price of at least $1.00 per share for its common stock.
The extension provides NeuroOne with additional time to address the compliance issue that began when the company's stock fell below the $1.00 threshold for 30 consecutive business days. As of the November 5 announcement, the company had not yet regained compliance with the minimum bid price requirement but informed Nasdaq of its intention to cure the deficiency within the extended timeframe. The current extension has no immediate effect on the company's listing status, which remains fully effective during this period.
NeuroOne's ability to maintain its Nasdaq listing carries significant implications for the company's visibility and access to capital markets. Delisting from a major exchange like Nasdaq could potentially limit investor access and reduce liquidity for current shareholders. The company stated it will continue monitoring its stock price and working toward compliance during the extension period. For more information about the company's technology and business focus, visit https://nmtc1.com.
If NeuroOne fails to meet the minimum bid price requirement by the May 2026 deadline, Nasdaq will issue a delisting notification. At that point, the company would have the right to appeal the determination to a Nasdaq Hearing Panel. However, the company acknowledged in its statement that there can be no assurance that such an appeal would be successful if needed.
The extension comes as NeuroOne continues developing its portfolio of medical technologies aimed at improving surgical care for patients with neurological conditions. The company's work includes solutions for EEG recording, monitoring, ablation, and stimulation for disorders such as epilepsy, Parkinson's disease, and chronic pain. The additional compliance period provides NeuroOne with critical time to demonstrate progress in both its clinical developments and market performance to investors.